Research An Interesting Report on The Use Of Psychoactive drugs for Treatment Of PTSD

Spacefish

Learning
Otago University (New Zealand) is currently running trials using slow release titrated doses of oral Ketamine for treatment resistant depression. Its been very successful, open to referral on compassionate grounds (for people who don't fit the trial criteria) and they're moving into phase 2 now and calling out for more participants.

Trials for new ketamine antidepressant report major breakthroughs in depression patients
Seventy-five percent of participants have reported a drastically-reduced score on the Montgomery-Asberg Depression Rating Scale (MADRS)
...
Upon commencing the study, patients were reporting scores in the 30s. MADRS scores of 20 or more indicate clinical depression. Scores of 30 or more indicate that the patient's quality of life and daily functioning is significantly impacted by their illness.

Dr Surman said that by day eight, patients were reporting an average MADRS score of 10.

"Below 12 is like all of us. We could all have a score like that," he said.
Trials for new ketamine antidepressant report major breakthroughs in depression patients

Oral ketamine tablets in patients with treatment resistant major depressive disorder – the Bedroc Study
Clinical trials, Department of Psychological Medicine, University of Otago, New Zealand

Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study
SAGE Journals: Your gateway to world-class research journals


My MADRS is around 35 and treatment options have not been too successful so this is very interesting and promising. Watching closely. :)
 
Top